Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03923959 · ClinicalTrials.gov registry record · Phase 3
Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population
A Phase 3 study, sponsored by Lancaster General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 283
- Enrollment target
NCT03923959 is a Phase 3 study that has completed, run by Lancaster General Hospital. The registered enrollment target is 283 participants.
The verdict
NCT03923959, a Phase 3 study, has completed, sponsored by Lancaster General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 283 participants
- Enrollment target
Study Summary
The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.
Interventions
- OTHER Placebo
- DRUG Tranexamic Acid Injectable Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 283 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03923959
The ClinicalTrials.gov registry entry for NCT03923959 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lancaster General Hospital, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03923959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03923959 about?
NCT03923959 is a clinical study titled "Evaluation of TXA Prior to Surgery in the Geriatric Hip Fracture Population". The overall design of the study is a prospective, double-blinded, randomized study in the geriatric hip fracture population comparing those who receive intravenous tranexamic acid prior to incision to those who receive a placebo.
What is the current status of trial NCT03923959?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 283 participants. The study started on 2020-02-01. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT03923959?
The interventions under investigation include: Placebo (OTHER), Tranexamic Acid Injectable Solution (DRUG).
Who is sponsoring clinical trial NCT03923959?
This trial is sponsored by Lancaster General Hospital, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.